India  

Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

Video Credit: HT Digital Content - Duration: 06:42s - Published
Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR

At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday.

Addressing a press conference in the national capital, he said, "At the present moment, we have three Indian vaccines which are in different phases of clinical testing.

The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine." "Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites," he added.

Dr Bhargava, however, said that social distancing and proper hygiene are the best "vaccine" available now and even after.

"Physical Distancing, wearing a mask, proper hand hygiene are the best vaccine available at the moment and even after.

We will have to continue with these measures," he said.

India has so far recorded over 18 lakh cases and more than 38,900 deaths.


You Might Like


💡 newsR Knowledge: Other News Mentions

Balram Bhargava Indian science administrator

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon [Video]

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon

Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.

Credit: HT Digital Content    Duration: 01:19Published
Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine [Video]

Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine

Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, "3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances."

Credit: ANI    Duration: 01:21Published
Second national sero-survey to be completed in September first week: ICMR [Video]

Second national sero-survey to be completed in September first week: ICMR

Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said, "ICMR sero survey is publication in-progress. It should appear by this week in the Indian Journal of Medical Research. It has been peer reviewed. The second national sero-survey should be completed in the first week September". On situation of COVID-19 vaccines in India, Balram Bhargava said, "Three COVID-19 vaccines are ahead in the race in India. Serum Institute's vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila's vaccines have completed phase 1 trial."

Credit: ANI    Duration: 01:49Published
Irresponsible people without masks are driving pandemic in India: ICMR [Video]

Irresponsible people without masks are driving pandemic in India: ICMR

Indian Council of Medical Research, Director General Balram Bhargava when asked on who is diving the pandemic, said, "Irresponsible, less cautious people who are not wearing masks are driving the pandemic in India." He further reacted on re-infection of one case in Hong Kong. He said, "We have read report on re-infection of one case in Hong Kong. It can depend on several factors. It could be related to the patient's immune status, whether the virus has mutated. We need to closely follow it up, but at the same time we don't need to be alarmed".

Credit: ANI    Duration: 01:15Published

Indian Council of Medical Research Indian Council of Medical Research organization

If all goes well, expect COVID vaccine by early next year: AIIMS doctor [Video]

If all goes well, expect COVID vaccine by early next year: AIIMS doctor

As clinical trials of different COVID-19 vaccines are in various phases across the globe, an AIIMS (All India Institute of Medical Sciences) doctor said that if everything goes as planned, people can expect a vaccine as early as the starting of next year. "Phase 2 clinical trial for COVID-19 vaccine is underway in India with a good sample size of more than 600 motivated volunteers. Any vaccine will come by mid-next year, if everything goes as planned," Community Medicine Department head added. On the Sero-survey conducted by Indian Council of Medical Research, Dr. Rai said the survey only shows the direction of infection while testing shows the actual number of infections.

Credit: ANI    Duration: 02:26Published
India's COVID recoveries cross 41 lakh mark, active infections past 10 lakh [Video]

India's COVID recoveries cross 41 lakh mark, active infections past 10 lakh

As per the data released by Ministry of Health and Family Welfare, India on September 18 reported single-day spike of 96,424 new coronavirus cases in the last 24 hours. 1,174 deaths in the same period, pushing the COVID-19 toll in the country to 84,372. India's confirmed cases of coronavirus are now 52,14,678 which include 10,17,754 active infections. More than 41,12,552 people have recovered from the deadly disease. According to Indian Council of Medical Research (ICMR), a total of 10,06,615 samples were tested on September 17. Cumulative samples tested for COVID-19 till September 17 are 6,15,72,343.

Credit: ANI    Duration: 01:38Published

COVID-19 testing: India breaches 6 crore-mark, last 2 crores in only 20 days, says ICMR

India conducted the last two crores sample testing in only 20 days.
DNA

India crosses 6 crore mark in Covid-19 testing; 11,36,613 samples tested in single day: ICMR

India has crossed the six crore mark in conducting tests for detection of Covid-19, with 6,05,65,728 samples having been examined till September 16, the Indian..
IndiaTimes

Serum Institute of India Serum Institute of India Indian biotechnological company, vaccine manufacturer

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the..
DNA
Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning [Video]

Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning

From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the months of October and November 2020 could be 'tougher' - here are the top news updates on the Covid-19 pandemic. Adar Poonawalla, chief executive of Serum Institute of India reportedly said that it might take 4-5 years for the vaccine to reach everyone. He estimated that around 1,500 crore vaccine doses would be required to inoculate everyone if the final vaccine is a 2-dose drug. Meanwhile, the Government of India banned the export of onions after a 30% jump in export of the kitchen staple in the April-July 2020 period. Over a dozen Members of Parliament were found to be Covid positive on the day the central legislative body convened for its monsoon session. In Delhi, the deputy Chief Minister, Manish Sisodia, tested positive on the day that the Chief Minister of neighbouring Haryana, Manohar Lal Khattar, finally recovered from the disease. Watch the full video for the other top updates on the spread of the Sars-CoV-2 coronavirus.

Credit: HT Digital Content    Duration: 02:18Published

Serum Institute of India to resume clinical trials of AstraZeneca-Oxford's COVID-19 vaccine after DGCI nod

The Pune-based Serum Institute of India (SII) is all set to resume the clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate AZD1222 after receiving..
DNA

Cadila Healthcare Cadila Healthcare Indian multinational pharmaceutical company

For high-risk groups, government plans to fast-track vaccine

India has three vaccines in advanced stages of trial. The vaccine candidate developed by Oxford University and AstraZeneca and proposed in India by Serum..
IndiaTimes

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Bharat Biotech’s Covid vaccine generated 'robust immune response' on animals

Hyderabad-based vaccine major Bharat Biotech has announced that its Covid-19 vaccine candidate Covaxin, during its testing on animal rhesus macaques, has develop..
IndiaTimes

Related news from verified sources

Serum gets DCGI nod for Phase 2 & 3 trials

India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage...
IndiaTimes - Published


Tweets about this


Related videos from verified sources

‘Flattening of Covid-19 curve requires collaborative efforts’: Harsh Vardhan [Video]

‘Flattening of Covid-19 curve requires collaborative efforts’: Harsh Vardhan

Union Health Minister Harsh vardhan spoke at a joint meeting with G20 finance and health ministers. Harsh Vardhan said that flattening of the curve requires collaborative efforts. "Current pandemic..

Credit: HT Digital Content     Duration: 04:24Published
‘Covid vaccine likely by early 2021’: Harsh Vardhan in Rajya Sabha [Video]

‘Covid vaccine likely by early 2021’: Harsh Vardhan in Rajya Sabha

Union Health Minister Harsh Vardhan on Thursday said that he is hopeful that by the early next year, the vaccine will be available in India and added that Prime Minister Narendra Modi has handled..

Credit: HT Digital Content     Duration: 03:09Published
Indians return from Pakistan: 400 people stranded amid Covid lockdown back [Video]

Indians return from Pakistan: 400 people stranded amid Covid lockdown back

Around 400 people reportedly returned from Pakistan to India via the Wagah-Attari border crossing. They were stuck in the neighbouring nation due to the Covid-19 pandemic and the consequent lockdown...

Credit: HT Digital Content     Duration: 03:00Published